Related Experiment Videos
Labelling monoclonal antibodies with yttrium-90
S J Mather1, D M Tolley, G W White
1Department of Nuclear Medicine, St. Bartholomews Hospital, London, UK.
European Journal of Nuclear Medicine
|January 1, 1989
Summary
Researchers optimized labeling of monoclonal antibodies with Yttrium-90 (90Y) using a DTPA method. High labeling efficiency was achieved, but radiolysis affected antibody function, impacting potential diagnostic and therapeutic applications.
Area of Science:
- Radiochemistry
- Immunology
- Oncology
Background:
- Monoclonal antibodies (mAbs) are crucial for targeted cancer therapy.
- Radiolabeling mAbs with Yttrium-90 (90Y) offers therapeutic potential.
- Optimizing the labeling process is essential for clinical efficacy.
Purpose of the Study:
- To optimize the cyclic DTPA derivatization procedure for labeling three tumor-associated monoclonal antibodies with 90Y.
- To achieve high labeling efficiencies and specific activities suitable for in vivo applications.
Main Methods:
- Utilized the cyclic DTPA derivatization method.
- Optimized reaction conditions for labeling three specific tumor-associated monoclonal antibodies.
- Assessed labeling efficiency, specific activity, and radiochemical stability.
Main Results:
- Achieved high labeling efficiencies (>95%) with Yttrium-90 (90Y).
- Obtained modest specific activities (1 mCi/mg) routinely.
- Demonstrated good in vitro radiochemical stability.
- Observed early losses in antibody immunoreactivity due to radiolysis.
Conclusions:
- The optimized DTPA method enables efficient radiolabeling of tumor-associated monoclonal antibodies with 90Y.
- Radiolysis poses a challenge, potentially limiting the in vivo effectiveness of 90Y-labeled antibodies.
- Further research is needed to mitigate radiolysis and preserve antibody immunoreactivity for improved therapeutic outcomes.